Cynthia Gill
08-07

Considering Novo Nordisk (NVO) and Eli Lilly (LLY) before earnings? Both have strong growth prospects, especially in diabetes care. Assess their financials and market position for a potentially rewarding investment. [Great][Great][Great]$Novo-Nordisk A/S(NVO)$ $Eli Lilly(LLY)$

LLY Beats vs. NVO Misses:Which Weight Loss Drug Do You Favor?
Eli Lilly expects fiscal year revenue to be between $45.4 billion and $46.6 billion, up from the previous forecast of $42.4 billion to $43.6 billion. Eli Lilly's stock surged 10% in pre-market trading. Novo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss. ------------ Which weight loss drug company is a better buy?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment